Cargando…

Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy

Standard therapy for secondary hyperparathyroidism (SHPT) includes dietary calcium supplementation, active vitamin D, and phosphate binders; however, these are often insufficient to allow patients to achieve their serum parathyroid hormone (PTH), calcium and calcium–phosphorus product (Ca × P) targe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frazão, João, Rodriguez, Mariano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421156/ https://www.ncbi.nlm.nih.gov/pubmed/25983950 http://dx.doi.org/10.1093/ndtplus/sfm039

Ejemplares similares

Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics
por: Cunningham, John, et al.
Publicado: (2008)

Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes
por: Pereira, Luciano, et al.
Publicado: (2018)

Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
por: Arenas, Maria Dolores, et al.
Publicado: (2020)

Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism
por: van der Plas, Willemijn Y., et al.
Publicado: (2016)

Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease
por: Abbas, Fizza, et al.
Publicado: (2019)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
por: Ni, Zhaohui, et al.
Publicado: (2023)

Real-World Evaluation of Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease, in an Italian Clinical Setting
por: Perrone, Valentina, et al.
Publicado: (2022)

Effects and Safety of Calcimimetics in End Stage Renal Disease Patients with Secondary Hyperparathyroidism: A Meta-Analysis
por: Zhang, Qian, et al.
Publicado: (2012)

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism
por: Yu, Longchuan, et al.
Publicado: (2017)

Relationship between patients’ characteristics and efficacy of calcimimetics for primary hyperparathyroidism in the elderly
por: Yamamoto, Koichiro, et al.
Publicado: (2022)

The importance of prevention of calciphylaxis in patients who are at risk and the potential fallibility of calcimimetics in the treatment of calciphylaxis for patients with secondary hyperparathyroidism
por: Khalpey, Zain, et al.
Publicado: (2010)

ODP102 Indicators for the effects of calcimimetics on hypercalcemia in the elderly patients with primary hyperparathyroidism.
por: Yamamoto, Koichro, et al.
Publicado: (2022)

Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
por: Wetmore, James B, et al.
Publicado: (2008)

A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
por: Ohya, Yuichiro, et al.
Publicado: (2018)

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan
por: Yokoyama, Keitaro, et al.
Publicado: (2020)

Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study
por: Mima, Akira, et al.
Publicado: (2018)

Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era
por: Conzo, Giovanni, et al.
Publicado: (2013)

A novel case of neonatal severe hyperparathyroidism successfully treated with a type II calcimimetic drug
por: Leunbach, T.L., et al.
Publicado: (2021)

Calcimimetics and outcomes in CKD
por: Drüeke, Tilman B
Publicado: (2013)

Novel Use of Calcimimetic Activity to Diagnose Primary Hyperparathyroidism in a Patient With Persistently Low-Normal Parathyroid Hormone Level
por: Bandaru, Sindhura, et al.
Publicado: (2020)

Potential Future Uses of Calcimimetics in Patients with Chronic Kidney Disease
por: Chonchol, Michel, et al.
Publicado: (2008)

Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease
por: Rodríguez-Ortiz, María E., et al.
Publicado: (2020)

Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?
por: Frazão, João M, et al.
Publicado: (2012)

Parathyroidectomy Versus Calcimimetic: The Lower the PTH the Better?
por: Evenepoel, Pieter, et al.
Publicado: (2022)

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study
por: Akizawa, Tadao, et al.
Publicado: (2018)

Calcimimetics in CKD—results from recent clinical studies
por: Schlieper, Georg, et al.
Publicado: (2008)

A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients
por: Fukagawa, Masafumi, et al.
Publicado: (2017)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy
por: Kincse, Gyöngyvér, et al.
Publicado: (2012)

Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease
por: Hou, Yi-Chou, et al.
Publicado: (2022)

Calcimimetic Use in Familial Hypocalciuric Hypercalcemia—A Perspective in Endocrinology
por: Marx, Stephen J.
Publicado: (2017)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
por: Takashi, Yuichi, et al.
Publicado: (2022)

Therapeutic Effect of Calcimimetics on Osteoclast–Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease
por: Hung, Kuo-Chin, et al.
Publicado: (2020)

Calcimimetic restores diabetic peripheral neuropathy by ameliorating apoptosis and improving autophagy
por: Chung, You Chul, et al.
Publicado: (2018)

Effect of Pretransplant Use of Calcimimetic on Parathyroid Function after Renal Transplantation
por: Bokuda, Kanako, et al.
Publicado: (2021)

Chemoenzymatic Approaches to the Synthesis of the Calcimimetic Agent Cinacalcet Employing Transaminases and Ketoreductases
por: Marx, Lisa, et al.
Publicado: (2018)

Changes in bone microarchitecture following parathyroidectomy in patients with secondary hyperparathyroidism
por: Ruderman, Irene, et al.
Publicado: (2021)

Efficacy of Early Treatment with Calcimimetics in Combination with Reduced Doses of Vitamin D Sterols in Dialysis Patients
por: Bushinsky, David A., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_bg6dsqp4tfdr4304pna3hlii4h